Perboric acid

Identification

Generic Name
Perboric acid
DrugBank Accession Number
DB13235
Background

Perboric acid is mainly found in its salt form of sodium perborate and it can be found as a monohydrate or tetrahydrate.1 It is one of the peroxy acid salts with very wide functionalities in industrial settings.8 Perboric acid in the form of sodium perborate is approved by Health Canada since 2004 to be used as a disinfectant of medical instruments.3 By the FDA, sodium perborate is approved as an ointment for the protection of poison ivy dermatitis.4

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 59.82
Monoisotopic: 60.001874
Chemical Formula
BHO3
Synonyms
Not Available

Pharmacology

Indication

In the industry, sodium perborate is used as a disinfectant. It is also part of the ingredients for detergents, bleach powders, and personal care formulations. In cosmetic products, perboric acid and mainly its salt are used as an oxidizing agent for dyeing or permanent waving.8

In dentistry, sodium perborate monohydrate is used as an aid for the removal of phlegm, mucus or other secretions associated with an occasional sore in the mouth, for cleansing minor wounds, for temporary cleanse of canker sore or for the removal of foreign materials in minor wounds.6

In ophthalmic preparations, sodium perborate is used as a preservative for products used for dry eye. This use is approved as this compound rapidly degrades to harmless byproducts.2

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofCanker sores oral••• •••••••••• ••• ••••••••
For therapyMinor wounds••• •••••••••• ••• ••••••••
Symptomatic treatment ofWound of the oral cavity••• •••••••••• ••• ••••••••
Symptomatic treatment ofMinor gum inflammation••• •••••••••• ••• ••••••••
Symptomatic treatment ofUlceration of the mouth••• •••••••••• ••• ••••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

No systemic effects are expected as it is highly unlikely that the substance will be systemically available.9

Mechanism of action

Perboric acid acts as a source of active oxygen.5 In contact with water, perboric acid hydrolyzes to hydrogen and borate.2 As an antiseptic, the formation of hydrogen peroxide oxidizes the cellular components of the surrounding bacteria and kills them.7

Absorption

Dermal absorption is assumed to be very low due to the high hydrophilicity of perboric acid and its ionic nature.9

Volume of distribution

As perboric acid and its sodium salt are rapidly degraded in the body, this pharmacokinetic property is studied in the terms of Sodium carbonate and Hydrogen peroxide.

Protein binding

As perboric acid and its sodium salt are rapidly degraded in the body, this pharmacokinetic property is studied in the terms of Sodium carbonate and Hydrogen peroxide.

Metabolism

If perboric acid or its sodium salt get in touch with body fluids, they will rapidly dissociate into hydrogen peroxide, carbonate and sodium ions which are naturally present in the body. The produced hydrogen peroxide is rapidly degraded in blood and tissues. As carbonate is part of the normal buffer system of the body it is unlikely to be absorbed in amounts that could disturb the normal balance of the body. The rest of the dissociation products are also not thought to produce any significant systemic modifications.9

Hover over products below to view reaction partners

Route of elimination

As perboric acid and its sodium salt are rapidly degraded in the body, this pharmacokinetic property is studied in the terms of Sodium carbonate and Hydrogen peroxide.

Half-life

As perboric acid and its sodium salt are rapidly degraded in the body, this pharmacokinetic property is studied in the terms of Sodium carbonate and Hydrogen peroxide.

Clearance

As perboric acid and its sodium salt are rapidly degraded in the body, this pharmacokinetic property is studied in the terms of Sodium carbonate and Hydrogen peroxide.[

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Acute oral and dermal LD50 are 1500 mg/kg and >2000 mg/kg, respectively. The toxicity of perboric acid and its salt is thought to be local and reported to be slight irritation of the skin which can be explained by the release of hydrogen peroxide. Mutagenicity, fertility and carcinogenicity studies have not been performed but it is thought that the potential of perboric acid to produce mutagenic, fertility or carcinogenic effects is unlikely.9

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Sodium perborateY52BK1W96C7632-04-4YKLJGMBLPUQQOI-UHFFFAOYSA-M
Sodium perborate monohydrateY9UKD0XE6F10332-33-9MDGXUEVTGARGDK-UHFFFAOYSA-M
Active Moieties
NameKindUNIICASInChI Key
Borate ionionic44OAE30D2212258-53-6GDTSJMKGXGJFGQ-UHFFFAOYSA-N
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Amosan Oral Wound CleanserPowder, for solution1.2 g/1.7gOralVintage Brands Limited2017-12-01Not applicableUS flag
Amosan Wound Cleanser Cherry FlavourPowder, for solution1.2 g/1.7gOralVintage Brands Limited2019-06-01Not applicableUS flag

Categories

ATC Codes
A01AB19 — Sodium perborate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as metalloid oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen is a metalloid.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Metalloid organides
Sub Class
Metalloid oxides
Direct Parent
Metalloid oxides
Alternative Parents
Metalloid salts / Inorganic salts / Inorganic oxides
Substituents
Inorganic metalloid salt / Inorganic oxide / Inorganic salt / Metalloid oxide
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
HC4C3M1FO2
CAS number
14034-78-7
InChI Key
PEYVWSJAZONVQK-UHFFFAOYSA-N
InChI
InChI=1S/BHO3/c2-1-4-3/h3H
IUPAC Name
boranoylperoxol
SMILES
OOB=O

References

General References
  1. Valera MC, Camargo CH, Carvalho CA, de Oliveira LD, Camargo SE, Rodrigues CM: Effectiveness of carbamide peroxide and sodium perborate in non-vital discolored teeth. J Appl Oral Sci. 2009 May-Jun;17(3):254-61. [Article]
  2. Troy B. and Beringer P. (2006). Remington: The Science and Practice of Pharmacy (21st ed.). Lippincott Williams & Wilkins.
  3. Health Canada [Link]
  4. FDA Poisonous Plant Database [Link]
  5. Manufacturer [Link]
  6. DailyMed Label: AMOSAN (Sodium perborate monohydrate) oral wound cleanser [Link]
  7. EPA [Link]
  8. Technical data sheet [File]
  9. OECD SIDS [File]
ChemSpider
102872
ChEBI
30175
ChEMBL
CHEMBL3707334
ZINC
ZINC000256057132
Wikipedia
Sodium_perborate
MSDS
Download (47.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Powder, for solutionOral1.2 g/1.7g
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)63 ºC but decomposes at 60 ºC'MSDS'
boiling point (°C)130-150 ºC but decomposes at 60 ºC'MSDS'
water solubility23 g/L'MSDS'
Predicted Properties
PropertyValueSource
logP0.48Chemaxon
pKa (Strongest Acidic)7.47Chemaxon
pKa (Strongest Basic)-6.1Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area46.53 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity5.36 m3·mol-1Chemaxon
Polarizability4.27 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-9000000000-dd54098450f4c08d8bdc
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-54a97079464ddbc8dea9
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-9000000000-dd54098450f4c08d8bdc
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-54a97079464ddbc8dea9
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-9000000000-9be10b4223414a7ba488
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-54a97079464ddbc8dea9
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at June 23, 2017 20:38 / Updated at April 24, 2024 13:53